Please login to the form below

Not currently logged in

Nycomed expands in China

Swiss pharma company Nycomed acquires majority stake in Guangdong Techpool Bio-Pharma

Nycomed is expanding its presence in China through the acquisition of a majority stake (51.34 per cent) in Guangdong Techpool Bio-Pharma Co (Techpool), a Chinese bio-pharmaceutical company.

Techpool, founded in 1993, specialises in the research, development, manufacturing and marketing of biologic drugs derived from natural sources. Its portfolio includes innovative protein drugs Ulinastatin, a broad-acting trypsin inhibitor, for the treatment of sepsis and multiple organ dysfunctions and Kallikrein, a serine protease, which is used in the treatment of stroke.

Techpool has a strong intellectual property position, including 35 patents filed, of which 17 have been granted, including one US patent approval.

Shanghai Pharmaceutical Group, a Chinese pharmaceutical conglomerate, holds 40.8 per cent of the shares of Techpool and was previously the majority shareholder.

Nycomed believes there is significant potential for continued strong growth of Techpool's key products through expanded hospital and reimbursement coverage in China. While Nycomed China and Techpool will be run as separate companies, value will be created through various alliances between them. The two companies will continue to expand in China, focusing on five core brands: Ulinastatin, Kallikrein, Pantoloc, Ebrantil and Actovegin.

Håkan Björklund, CEO of Nycomed, said: "Techpool's speciality franchise is highly complementary to Nycomed's development strategy and will become a cornerstone of our international expansion in emerging markets."

Techpool's management team, headed by the founder and CEO Dr Fu, will play a pivotal role in Nycomed's future expansion and the alliance has the support of Techpool's existing shareholders, including Shanghai Pharmaceutical Group.

Techpool has a marketing network spanning the whole of China and its products are distributed throughout Japan, South Korea, India and Pakistan, among other countries.

Nycomed has branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management, along with a range of OTC products.

2nd November 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...